SARS-CoV-2 vaccine development is of major importance for COVID-19 control but is mainly biased toward neutralizing antibody protection, which generally less effectively elicits CD8+ T cell responses and faces possible risks during the clearing of the virus and preventing infection. The gene discussed is CD8A; the disease is infection.